{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:19:33Z","timestamp":1792084773968,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T00:00:00Z","timestamp":1160352000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A combination treatment with a mood stabilizer and an antipsychotic drug is often used in as many as 90% of subjects with acute mania. Recently, augmentation therapy with atypical antipsychotics has been investigated in both the acute and long\u2010term treatment of bipolar disorder with or without psychosis. In the present study, the authors investigated the efficacy of risperidone treatment for both acute manic and depressive episodes in bipolar disorder. Eighteen patients (M\/F: 8\/10, age: 34\u2009\u00b1\u200915\u2009yr) who met the DSM\u2010IV criteria for bipolar I disorder (12 cases of manic episodes, 6 cases of depressive episodes) with risperidone treatment were evaluated regarding their clinical improvement using the Young Mania rating Scale (YMRS) and the Hamilton rating Scale for Depression (Ham\u2010D). Plasma concentrations of HVA and MHPG were analyzed by HPLC\u2010ECD and plasma brain\u2010derived neurotrophic factor (BDNF) levels were detected by sandwich ELISA. The mean scores of the YMRS were 22, 18, 12, 8, and 5 at time points before and 1, 2, 3, and 4 weeks after the risperidone administration, respectively. The mean scores of the Ham\u2010D were 24, 25, 21, 21, and 19 at time points before and 1, 2, 3, and 4 weeks after the risperidone administration, respectively. The plasma levels of HVA and 3\u2010methoxy\u20104\u2010hydroxyphenylglycol (MHPG) were observed to have decreased 4 weeks after risperidone administration in manic patients. The levels did not change in depressive patients. The plasma levels of BDNF were decreased in depressive patients compared with manic patients or healthy controls. However, the administration of risperidone did not alter plasma BDNF levels. Copyright \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.804","type":"journal-article","created":{"date-parts":[[2006,10,9]],"date-time":"2006-10-09T10:03:27Z","timestamp":1160388207000},"page":"433-438","source":"Crossref","is-referenced-by-count":40,"title":["Effect of risperidone on plasma catecholamine metabolites and brain\u2010derived neurotrophic factor in patients with bipolar disorders"],"prefix":"10.1002","volume":"21","author":[{"given":"Reiji","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Ikenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,9]]},"reference":[{"issue":"4","key":"e_1_2_1_2_1","first-page":"1","article-title":"Practice Guideline for the Treatment of patients with Bipolar Disorder (revision)","volume":"159","author":"American Psychiatric Association","year":"2002","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.00020.x"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1977.tb07739.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0518"},{"key":"e_1_2_1_6_1","first-page":"135","article-title":"Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites","volume":"1","author":"Bowers MB","year":"1977","journal-title":"Community Psychopharmacol"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1322-9"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199711000-00006"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2004.02.003"},{"key":"e_1_2_1_10_1","first-page":"423","article-title":"Risperidone in the treatment of affective illness and obsessive\u2010compulsive disorder","volume":"56","author":"Jacobsen FM","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200503000-00002"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00529-3"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00005-7"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200103000-00005"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00159-6"},{"key":"e_1_2_1_16_1","first-page":"218","article-title":"The antidepressant effects of risperidone and olanzapine in bipolar disorder","volume":"11","author":"Mclntyre RS","year":"2004","journal-title":"Can J Pharmacol"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1210"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199906000-00002"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(98)00141-5"},{"key":"e_1_2_1_20_1","first-page":"1","article-title":"The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder","author":"Sachs GS","year":"2000","journal-title":"Postgard Med Apr"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_1_22_1","first-page":"55","article-title":"Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania","volume":"32","author":"Sajatovic M","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_23_1","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double\u2010blind randomized controlled trial","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1218"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00181-1"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.4.396"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1987.01800160057008"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1978.tb06924.x"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00481-5"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0715"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00005"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015030-00007"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002139900339"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200303000-00008"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.01.008"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.685"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-931542"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.804","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T09:33:41Z","timestamp":1700040821000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1002\/hup.804"],"URL":"https:\/\/doi.org\/10.1002\/hup.804","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}